SERPINF2 and systemic sclerosis: Therapeutic strategies aimed at restoring fibrinolytic equilibrium—such as α2AP inhibition or modulation of uPAR signaling—may offer promising approaches to limit disease progression and target the underlying fibrotic and immunological mechanisms of SSc.